FDA cleared distinct CyMedica Orthopedics offers e-vive, an FDA-cleared, app-based muscle stimulation platform focused on knee osteoarthritis and post-surgical rehabilitation, presenting a unique entry point for physicians and clinics seeking non-pharmacologic, device-assisted rehabilitation options.

Integrated data platform The e-vive system collects rehabilitation data to measure and promote patient progress, enabling value-based discussions with healthcare providers and potential upsell opportunities around outcomes tracking, remote monitoring, and data-driven care plans.

Growth via product line Recent launch of Motive Knee expands the product family to address knee pain and muscle weakness, signaling expansion opportunities with orthopedic clinics and hospitals looking to standardize muscle strengthening therapies across knee care pathways.

Strategic financing Past financing rounds and a multimillion-dollar funding pool indicate investor confidence and available capital to support sales efforts, channel partnerships, and potential expansion into larger clinical settings or networks.

Market positioning Operating with a small team yet targeting large orthopedic players with extensive hospital systems (e.g., Arthrex, Stryker, Zimmer Biomet as comparables), CyMedica can pursue channel partnerships, distributor agreements, and OEM-like collaborations to scale outreach and adoption within fast-growing orthopedic rehabilitation markets.